KARPAS 422 Human B-cell Non-Hodgkin’s Lymphoma Cell Line

KARPAS 422 Human B-cell Non-Hodgkin’s Lymphoma cell line useful in oncology research, developed at the University of Cambridge
Technology No.

Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio. We have partnered with ECACC (The European Collection of Cell Cultures; a Public Health England Culture Collection) to manage distribution of the majority of these cells on our behalf. Please request the cell line through ECACC before purchasing your licence via this site.

Internal Research Licence - 1 Year
1-year non-exclusive licence agreement for use of the Karpas 422 Cell Line for internal research only.

Term: 12 months

Price on approval

Sign up to our newsletter

If you would like to keep up to date with the latest opportunities, please sign up to our newsletter.